Comparing Outcomes after Oncoplastic Breast Reduction and
Breast Reduction for Benign Macromastia
by Marano, Andrew A.; Grover, Karan; Peysakhovich, Anya;
Lin, Alexandra J.; Castillo, Wendy; Rohde, Christine H
Plastic and Reconstructive Surgery: March 2022 -
Volume 149 - Issue 3 - p 541-548
Background: Oncoplastic breast reconstruction improves
cosmetic outcomes when compared to standard breast conservation therapy alone.
The authors studied whether tailoring a breast reduction to a cancer resection
affects complication rates by comparing (1) outcomes between oncoplastic and
benign macromastia patients and (2) complication rates between the cancer side
and the symmetrizing side of an oncoplastic reduction.
Methods: A retrospective chart review was performed on
female patients who underwent either oncoplastic or benign breast reduction
over 9 years by a single surgeon. Patient demographics, intraoperative data,
and postoperative outcomes were gathered from the electronic medical record.
Chi-square and t tests were performed when appropriate to determine
significance.
Results: Of the 211 patients included in the study, 62 (29.4
percent) underwent oncoplastic breast reduction and 149 (70.6 percent)
underwent breast reduction for benign macromastia. Total resection weight was
greater in the benign group (p = 0.00). There was a higher rate of loss of
nipple sensation in the oncoplastic group (p = 0.005) but no differences in any
other complication. There was a higher complication rate in the oncologic
breast when compared to the symmetrizing breast within the oncoplastic cohort
(p = 0.039), but no differences in the rates of individual complications.
Conclusions: Although the loss of nipple sensation was
increased in patients undergoing oncoplastic breast reduction, all other
outcomes were not significantly different between the two groups. The authors’
findings indicate that oncoplastic breast reduction can be performed with a
safety profile similar to that of a standard breast reduction. CLINICAL
QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
